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Edited by Robert BaroukiAbstract Non-conventional major histocompatibility complex
class I molecules are involved in a variety of physiological
functions, most at the periphery of the immune system per se.
Zinc-a2-glycoprotein (ZAG), the sole soluble member of this
superfamily has been implicated in cachexia, a poorly understood
yet life-threatening, severe wasting syndrome. To further ascer-
tain the role of ZAG in lipid metabolism and perhaps the immune
system, we inactivated both ZAG alleles by gene targeting in
mice. Subjecting these ZAG deﬁcient animals to standard or
lipid rich food regimens led to increased body weight in compar-
ison to identically treated wild-type mice. This phenotype
appeared to correlate with a signiﬁcant decrease in adipocytic
lipolysis that could not be rescued by several pharmacological
agents including b3-adrenoreceptor agonists. Furthermore, in
contrast to previously reported data, ZAG was found to be
ubiquitously and constitutively expressed, with an especially high
level in the mouse liver. No overt immunological phenotype was
identiﬁed in these animals.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Non-classical MHC1. Introduction
Conventional major histocompatibility complex (MHC)
class I molecules sample the intracellular antigenic repertoire,
for presentation to the ab T cell receptor of cytotoxic T lym-
phocytes, thereby initiating adaptive immunity [1]. They are
deﬁned by polymorphic, membrane-bound, MHC (chromo-
some 6 in man and 17 in mus)-encoded heavy chains which
heterodimerize with the non-MHC encoded immunoglobulin
(Ig)-like b2-microglobulin (b2m). Members of a distinct, heter-Abbreviations: MHC, major histocompatibility complex; ZAG, zinc-
a2-glycoprotein; LMF, lipid mobilizing factor; IBMX, isobutylmeth-
ylxanthine; FK, forskolin; WAT, white adipose tissue; BAT, brown
adipose tissue
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doi:10.1016/j.febslet.2006.12.047ogeneous lineage of MHC-I genes, including zinc-alpha-2-gly-
coprotein (ZAG), have been implicated in a variety of diverse,
yet crucial physiological functions. These include anti-infec-
tious/tumor immunity for MIC [2,3], iron homeostasis for
HFE [4] and trans-epithelial transfer of IgG for FcRn [5].
ZAG is the sole bona ﬁde soluble MHC-I protein (devoid of
transmembrane and cytoplasmic sequences), consisting of a
single polypeptide chain that is widely distributed in body ﬂu-
ids. ZAG’s structure resembles that of an archetypical MHC-I
molecule with a membrane distal a1–a2 ligand-binding super-
domain that incidentally, does not appear to bind a peptide,
but rather a small hydrophobic entity, most likely fatty acid
[6,7]. Unlike most other class I genes (with the exception of
human MIC glycoproteins) ZAG acts independently of b2m
[6].
ZAG was initially identiﬁed over 40 years ago [8], yet our
knowledge of its biological function(s) remains rudimentary.
The discovery that ZAG shares sequence identity with a long
sought, lipid mobilizing factor (LMF), ﬁrst implicated ZAG
in lipid metabolism [9,10]. Subsequently, a variety of circum-
stantial evidence has supported the idea that ZAG play a role
in cachexia [11], a severe life-threatening wasting syndrome
deﬁned by massive depletion of both adipose and skeletal mus-
cle tissues. Cachexia occurs in a number of patients suﬀering
from cancer, AIDS, and other chronic illnesses. Cachectic pa-
tients have indeed been found to have an elevated level of ZAG
in both serum and urine that appears to parallel weight loss [9].
Both ZAG and LMF induce lipolysis directly by stimulation of
adipocyte adenylyl cyclase, and in mice appear to produce a
dose-dependent decrease in body weight [12].
However, most if not all the biological data on ZAG has
stemmed from biochemical preparations of the molecule iso-
lated from various biological ﬂuids. The inherent heterogeneity
of these preparations might explain the plethora of biological
functions ascribed to this single molecule. In addition to
cachexia, these include a role in prostate cancer [13,14], blad-
der cancer [15], frontotemporal dementia [16], obesity [17], reg-
ulation of melanin production by melanocytes [18], cell-cycle
dependant inhibition of cell proliferation via, perhaps, down
regulation of cdc2 cyclin dependant kinase [19], inhibition of
the proliferation of hepatic stellate cells [20], a role in psoriatic
skin via adverse reaction to interferon-c treatment [21], action
as a cell adhesion molecule [22], ribonuclease activity [23], etc.
At the receptor-ligand level the situation is not clearer. What,blished by Elsevier B.V. All rights reserved.
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port has suggested binding to b3-adrenoreceptor [24]. There
have also been conﬂicting data with regard to ZAG’s expres-
sion pattern; both at transcriptional and/or protein level
[25–27]. Finally, the possible involvement of ZAG in immunity
remains an open question, especially as ZAG carries a putative
hydrophobic ligand and in this sense is reminiscent of CD1,
another non-conventional MHC-I molecule involved in pre-
senting glycolipidic moieties to NKT cells [28].
Generation and analysis of ZAG deﬁcient mice will there-
fore help answer a number of questions regarding the patho-
physiology of ZAG.2. Materials and methods
2.1. Gene targeting in embryonic stem cells and generation of ZAG
deﬁcient mice
The targeting construct was designed to independently delete the a1
and a2 domains of ZAG. To do this, four fragments were ampliﬁed
using the oligonucleotide pairs shown (Supplementary Table S1) andFig. 1. Inactivation of ZAG by homologous recombination. (A) Scheme of e
excision by Cre (Bottom). (B) Southern blot of multiple digests of correctly
(Right) external probes. (C) Northern blot analysis of liver and kidney of hom
loaded were probed either with ZAG cDNA (Top) or with HPRT cDNA
mZAG as positive control and lysates from various organs from ZAG deﬁcie
PstI; pgk-neor: neomycine resistance gene driven by the phosphoglycerate
ZAG+/: heterozygous ZAG mutant; ZAG/: homozygous ZAG mutant; H
tissue, BAT: brown adipose tissue; sc: subcutaneous; abdo: abdominal.E14.1 genomic DNA as a template. The fragments were sequentially
cloned into pBluescript, and a pgk-neor gene was inserted into the XhoI
site created in fragment 2. Restriction sites (EcoRI and BglII) were
introduced to tag the truncated exons 1 and 2, which encode the a1
and a2 domains. The construct was digested with KpnI and NotI
and puriﬁed to remove plasmid sequence. Targeting was carried out
as previously described [4]. Brieﬂy, 20 lg of puriﬁed fragment was elec-
troporated into 1 · 107 E14.1 ES cells and colonies picked after selec-
tion in G418. Two hundred and eighty two colonies were expanded in
duplicate and one set screened by Southern blot analysis with an exter-
nal probe (Fig. 1B). One correctly targeted clone (conﬁrmed with mul-
tiple digests, 5 0, 3 0 and internal probes) was injected into C57BL/6
blastocysts. Chimeras were backcrossed once and further intercrossed
to generate and to generate ZAG/ mice (Fig. 1A). Mice were
genotyped by PCR of tail DNA using the following oligos: ZAG
(9292–9312): 5 0 ACT CTG TGC CAG GCT CAG GTG 3 0; ZAG
(9747-9727) : 5 0 ACC ACA GGT CAG TCT GAT TAC 3 0; Pgk-neo
3 0 (14,309) : 5 0 GAG ATC AGC AGC CTC TGT TCC 3 0; Endoge-
nous = 456 bp, Neo insertion = 519 bp, Neo deletion = 550 bp. Total
RNA from liver and kidney was isolated from wild-type and ZAG/
mice, subjected to Northern blot analysis and probed with full-length
ZAG and HPRT cDNAs (Fig. 1C). Mice used in this study – both
knockouts and wild-types – were on a mixed C57BL/6 · 129P2/OlaHsd
background.ndogenous ZAG (Top), targeting construct (Middle) and post pgk-neor
targeted clone (+/) and E14.1 control (+/+) using the 5 0 (Left) or 3 0
ozygous mice ZAG+/+ and ZAG / . Two blots with the same samples
(Bottom). (D) Western blot on lysates of HeLa cells transfected with
nt and +/+ animals. Abbreviation: B: BamHI, E: EcoRI, H: HindIII: P:
kinase promoter; loxP: recombination sites for the Cre recombinase;
PRT: hypoxanthine-phosphoribosyl transferase; WAT: white adipose
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The full-length mZAG cDNA, including the endogenous secretory
signal sequence was cloned from mouse liver. Total liver RNA was ex-
tracted using TRIZOL (Invitrogen, Cergy Pontoise, France). Upon re-
verse transcription, polymerase chain reaction was performed using
‘‘Expand Long template PCR System’’ following manufacturer’s
instructions (Roche Diagnostics, Meylan, France), together with the
sense primer 5 0 GCA AGA ATG GTG CCT GTC CT 3 0 and reverse
primer 5 0 GGG TAA CTT ACT GAG GCT GA 3 0. The unique band
obtained at 930 bp was cloned into pCR2.1 using the TA cloning Kit
(Invitrogen). The integrity of the sequence was veriﬁed by DNA
sequencing (ABI PRISM 3100 Genetic Analyzer, Applied Biosystems,
USA). The thus obtained mZAG cDNA was subsequently inserted
into pcDNA3 expression vector. For transient expression, HeLa cells
(0.2 · 106) were transfected using 6 ll of Jet PEI (Polyplus transfec-
tion, Illkirch, France) precomplexed with 3 lg of circular pcDNA
mZAG. Forty-eight hours later, the cells were collected for further
analysis. To generate stable ZAG expressing cell line, CHO-K1 cells
(7 · 106) were transfected by electroporation with pcDNA mZAG.
The medium was removed 48 h after transfection and replaced by fresh
complete medium containing 0.5 mg/ml geneticin (Invitrogen). Individ-
ual geneticin resistant clones were picked out of the plate, expanded
and subjected to limited dilutions in 96-well plates. The best mZAG
expressing clones were further expanded.2.3. Cell lysis and immunoblotting procedures
Proteins were isolated from HeLa and CHO-K1 cells transfected or
not with pcDNA mZAG, and from mouse tissues, in the lysis buﬀer
(150 mM NaCl, 50 mM Tris–HCl, pH 8, 0.5 mM EDTA, 1% NP-40,
10% glycerol) containing a cocktail of protease inhibitors (Complete
EDTA-free, Roche Molecular Diagnostics, Meylan, France). Each tis-
sue was destroyed using a Polytron. Cell and tissue lysates were left 15
minutes on ice and centrifuged at 4 C 15 min at 13000 · g. The super-
natant was kept at 80 C for further analysis. Total protein concen-
tration of each sample was determined using the Bradford Assay
(Protein Assay, Biorad, Ivry sur Seine, France) and bovine serum albu-
min as a standard. Samples containing 40 lg of protein were mixed
with Laemmli buﬀer and boiled for 5 min. Each sample was subjected
to electrophoresis either on a 12% polyacrylamide gel (BioRad), or on
a 12% ProSieve gel (Cambrex Bio Science, Emerainville, France), and
semi-dry blotted onto Hybond-C Extra membrane (Amersham Phar-
macia Biotech). Protein Rainbow molecular-mass standards (Amer-
sham Pharmacia Biotech) were loaded simultaneously with the
samples. Equal loading was conﬁrmed by Ponceau S staining of the
membranes (Sigma-Aldrich). ZAG was then revealed with the E-20
antibody (Santa Cruz Biotechnology, USA), using the ECL System
(Amersham Pharmacia Biotech).2.4. Tunicamycin treatment and deglycosylation
Sub-conﬂuent cells (90-mm dish) were treated with tunicamycin
(5 lg/ml) (Sigma-Aldrich) or with DMSO alone for 6 h at 37 C in
complete medium in humidiﬁed atmosphere containing 5% CO2. The
cells were lysed as described and the samples were separated on a
12% ProSieve gel (Cambrex Bio Science), and mZAG was revealed fol-
lowing immunoblotting. For deglycosylation, tissue or cell lysates
(containing 100 lg of total protein in 50 ll of lysis buﬀer) were diluted
in 50 ll of 2X incubation buﬀer (40 mM sodium phosphate pH 7.2,
0.2% SDS, 2% (v/v) b-mercaptoethanol, 1% NP40, protease inhibitors)
and incubated overnight at 37 C with shaking, alone or with 2 U
N-glycosidase-F (Roche Molecular Diagnostics). Then, 20 ll of each
samples were run on a 12% ProSieve gel and ZAG was revealed follow-
ing immunoblotting with the E-20 antibody (Santa Cruz Antibodies).2.5. Animal conditions and food intake
Animals were group-housed at 21 C and had free access to food and
water. Mice were weaned at the age of three weeks onto standard diet.
At the age of ﬁve weeks, the groups were submitted to diﬀerent diets
with the following composition (as a percentage of total calories):
Standard Food (SF: 320 kcal/100 g, protein 20%, fat 10% and carbohy-
drates 70%) (n = 43 wild-type and n = 48 knockout mice) or High Fat
Diet (HFD: 556 kcal/100 g, protein 15%, fat 59% (lard), carbohydrates
26%) (Safe, Augy, France) (n = 30 wild-type and n = 26 knockout
mice). The body weight was measured weekly from week 5 to 23. Allexperiments were performed on male animals. The quantity (weight)
of food provided to each animal cage was monitored throughout the
experiments.
2.6. Lipolytic assay
Epididymal adipose tissue was quickly dissected and adipocytes were
isolated in Krebs–Ringer bicarbonate buﬀer containing collagenase
(1 mg/ml). Fat cells were incubated at 37 C in the presence of the dif-
ferent agents and shaken gently for 90 min, the glycerol released was
determined and expressed as previously described [29].2.7. Real-Time RT-PCR
Total RNA was isolated from diﬀerent liquid nitrogen frozen tissues
using either TRIZOL (Invitrogen), guanidium isothiocyanate followed
by cesium chloride gradient, or RNeasy Lipid Tissue Midi Kit (Qiagen,
Courtaboeuf, France). After reverse transcription of 1 lg of total
RNA by ImProm-II Reverse Transcriptase (Promega), quantiﬁca-
tion of murine ZAG mRNA was performed with ABI PRISM 7000
(Applied Biosystems), using SYBR GREEN PCR Master Mix (Ap-
plied Biosystems). PRIMER EXPRESS software (Applied Biosystems)
was used to design the following primers: ZAG: 5 0 GGA CAC TAC
AGG GTC TCA CAC CTT 3 0 (forward), 5 0 TGA AAT CCT CTC
CGT CGT AGG C 3 0 (reverse) and 18S: 5 0 CGG CTA CCA CAT
CCA AGG AA 3 0 (forward), 5 0 GCT GGA ATT ACC GCG GCT
3 0 (reverse). The PCR parameters were as follow: 2 min at 50 C,
10 min at 95 C followed by 40 cycles of denaturation at 95 C for
15 s, and annealing and extension at 60 C for 1 min. Ampliﬁcation
was performed in a ﬁnal volume of 25 ll, and each sample contained
5 ll cDNA (equivalent to 12.5 ng of RNA), 300 nM of ZAG forward
and reverse primers or 100 nM of 18S forward and reverse primers,
and 12.5 ll of SYBR GREEN PCRMaster Mix (Applied Biosystems).
The size of ZAG and 18S amplicons were 107 bp and 186 bp, respec-
tively. Each quantitative PCR reaction was performed in duplicate,
and the mean value of Ct for each sample was used in data analysis.
All samples were normalized to the 18S values and the results
expressed as fold changes of Ct value relative to controls by using
the 2DDCt formula [30].
2.8. Biochemical and immunological parameters
All biochemical parameters were performed at the Clinique de la
Souris (Illkirch, France) following standard procedures [31]. A preli-
minary phenotyping of lymphoid compartments was achieved using
previously published methods [4].2.9. Statistics
Statistical analysis was performed with StatView 5.0 software (SAS
Institute, Cary, NC). The diﬀerences of body weight after SF or HFD
feeding between ZAG/ mice and normal mice was assessed with
unpaired t-tests (Student’s t-test). P-value < 0.05 was considered signif-
icant.3. Results
ZAG was inactivated by homologous recombination in
embryonic stem cells by mutating the second and third exons
(Fig. 1A), leading to truncated a1 and a2 domains. Gene tar-
geting of neomycin resistant clones was analyzed by Southern
blotting (Fig. 1B). A heterozygote embryonic stem cell clone
was used to generate mutant mice using standard procedures.
ZAG/ mutant mice were completely devoid of ZAG tran-
script and protein as, respectively, judged by Northern blot
analysis of liver and kidney (Fig. 1C) and Western blotting
of liver, kidney, fat depots and serum (Fig. 1D), heart, lung,
stomach, intestine, spleen, brain and testis (data not shown).
Lysates of HeLa cells transfected with murine ZAG (mZAG)
cDNA were used as positive control (Fig. 1D).
Mice lacking ZAG were viable, fertile and displayed no
gross abnormal phenotype. Throughout normal mouse
V. Rolli et al. / FEBS Letters 581 (2007) 394–400 397husbandry, it became apparent however, that occasionally,
ZAG deﬁcient mice displayed peculiar (quantitatively and
qualitatively) fat repartition (cf. below). Given this observation
and especially background knowledge on ZAG (see Section 1),
and in order to conclusively gauge the intervention of ZAG in
lipid metabolism, the following experiments were set up.
Body weight was monitored over a period of time ranging
from the ages of 5 to over 23 weeks. Two large cohorts of
ZAG deﬁcient and wild-type littermate mice were constituted.
One was fed with ‘‘standard food’’ (SF) whereas the other with
a ‘‘High Fat Diet’’ alimentation (HFD). Although ZAG/
gained signiﬁcantly more weight than ZAG+/+ control animals
in both groups, this was more pronounced in the animals
following HFD (Fig. 2). In addition to total body weight, indi-
vidual organs were also regularly weighed, the livers from
ZAG/ mice were signiﬁcantly heavier than those from
wild-type animals (HFD diet) (data not shown). These cohorts15
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obtained in control mice was performed using Student t-test *P < 0.05.of animals were assessed using a number of standard biochemi-
cal parameters. Among these the basal levels of glucose,
insulin, triglycerides, free fatty acids and leptin were not signiﬁ-
cantly diﬀerent in overnight fasted wild-type versus knock-out
animals submitted to SF or HFD (data not shown). It should
be noted that weight gain was independent of food intake as
regular monitoring of such, did not show any signiﬁcant diﬀer-
ence between wild-type and knock-out animals.
Since ZAG has been shown to stimulate lipolysis in mice
[10], we aimed to assess the state of lipolysis in the absence
of ZAG. Lipolysis was induced by diﬀerent agents e.g. for-
skolin (FK) that increases cAMP formation, isobutylmethyl-
xanthine (IBMX) which augments also cAMP levels but
through inhibition of phosphodiesterase activity, isoprenaline,
a non selective b-adrenergic agonist and ﬁnally CL316243, a
speciﬁc b3-adrenergic agonist. As shown in Fig. 3, spontaneous
basal lipolysis in epidydymal adipocytes was not signiﬁcantly15
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/ 100 mg lipid / 90 min glycerol release from adipocytes of
ZAG+/+ and ZAG/ mice, respectively. Dose–response curves
of both isoprenaline and CL316243 agents were signiﬁcantly
decreased in adipocytes of ZAG/ mice, suggesting that this
eﬀect was not b3-adrenergic speciﬁc. In addition, the lipolytic
eﬀects of FK (105 M) and IBMX (103 M) were signiﬁcantly
lower in adipocytes of ZAG/ mice compared to controls.
Thus, adipocytes of ZAG knockout mice presented a general
decrease of lipolysis.B
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Fig. 4. ZAG gene expression in mouse tissues by real-time RT-PCR.
mRNA levels were normalized to 18S RNA. Relative Quantiﬁcation
(RQ) of ZAG mRNA of heart, lung, liver, stomach, small intestine,
spleen, kidney, brain, testis, subcutaneous WAT, abdominal WAT,
interscapular WAT and BAT from wild-type mice and liver of ZAG/
mice were given relative to heart. Results are means ± S.D. of 4–8
determinations on 2–4 diﬀerent RNA extractions. They are represented
in logarithmic scale.The expression pattern of ZAG was assessed both at the level
of mRNA and protein. Real-time quantitative RT-PCR (RT-
qPCR) of ZAG transcript in various mouse tissues detected
a strong signal in liver compared with weaker signals in all
other tissues tested: heart, lung, stomach, intestine, spleen, kid-
ney, brain, testis as well as various fat depots i.e. subcutaneous
white adipose tissue (WAT), abdominal WAT and interscapu-
lar brown adipose tissue (BAT) (Fig. 4). However, each exam-
ined tissue did express ZAG, compared to the hepatic value in
ZAG/ mice which is zero. Western blot analyses were also
performed in a number of ZAG+/+ tissues. ZAG protein was
observed in each tissue tested (Fig. 5A); the existence of multi-
ple bands within the 38–43 kDa range was suggestive of glyco-
sylation (there are three potential N-linked glycosylation sites
in murine ZAG vs. 4 in man where actually three are glycosyl-
ated as assessed by X-ray crystallography). In order to be sure
that these ﬂuctuations are indeed associated with variations in
the glycosylation state of ZAG [32], and that they are not non
speciﬁc bands, deglycosylation and tunicamycin treatments
were performed. A CHO cell line expressing mZAG was trea-
ted with tunicamycin. The cells were lysed and show ZAG
totally deglycosylated at around 31 kDa (Fig. 5B). A CHO cell
lysate expressing mZAG was treated with N-glycosidase F
(Fig. 5B). In conclusion, deglycosylated ZAG and non-glycos-
ylated ZAG migrate at the same level. Thus, each lysate of the
tissues collected was treated with N-glycosidase F, and all of
them showed the deglycosylated form of ZAG, as nothing is
seen in ZAG/ mice (Fig. 5C). Therefore, the characterization
of wild-type control mice revealed that ZAG protein is ubiqui-
tously and constitutively expressed, with an especially high
level in the liver compared to other tissues tested.4. Discussion
Given the initial (and even present) surprising structuring of
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most plausible scenario for the involvement of ZAG in the im-
mune system would be through its capacity to bind and pres-
ent, a lipidic entity, to T cells, not dissimilar from the
interaction involving another non-conventional MHC class I
molecule, CD1, which NKT cells [28]. Not withstanding this
hypothesis, and comforted by several reports hinting at the
capacity of ZAG to bind lipidic moieties [6,7,33], it is a general
understanding that ZAG intervenes in the complex lipid
metabolism pathway, although it will be of great help, if a sim-
ple genetic system was available to the examine the issue in live
animals. Last, but not least, a myriad of papers have linked
ZAG to a disconcerting range of biological activities, which
collectively are diﬃcult to reconcile with the action of a single
molecule (cf. introduction), and therefore need to be sorted
out.
In order to unequivocally probe the deﬁnite range of ZAG’s
pathophysiology, we ablated both ZAG alleles in the mouse
genome through standard gene-targeting technology. Firstly,
it was clearly shown that ZAG KO mice were overweight with
respect to wild-type littermates inferring the opposite, i.e. ZAG
overexpression should lead to weight loss and eventually
cachexia, a result in line with the literature on the subject.
Although, at gross anatomical level, this phenotype could
not be ascribed to a single organ, given the episodic occurrence
of abnormal fat repartition (as documented by Magnetic Res-
onance Imagery; data not shown) resembling lipodystrophic
syndromes (which could not be systemically observed given
most likely the mixed genetic background of studied cohorts)
we decided to concentrate our eﬀorts on the adipose tissue.
The subsequent results on isolated adipocytes show a signiﬁ-
cant decrease of stimulated lipolysis in the absence of ZAG
which could not be rescued using an array of agonists func-
tioning upstream or downstream of adenylyl cyclase. These
also included a b3-adrenergic agonist: the CL316243 (Fig. 3).
Although even lower concentrations of CL316243 could have
been used to better characterize the dose–response curve, these
data collectively demonstrate, that in contrast to previous
reports, ZAG does not appear to signal via the adrenoreceptor
pathway [24]. Moreover, the level of b3-adrenoreceptor did not
show any diﬀerence in ZAG+/+ vs. / mice as evidenced by
RT-qPCR (data not shown). These results are consistent with
the fact that in human adipocytes, b3-adrenoreceptor mRNA
is expressed at a much lower level than in mouse [34]. Since
ZAG leads to fat depletion in mouse and human, it is likely
therefore that a common mechanism is used in both species.
Finally, given the central role of Hormone-sensitive lipase
(HSL) in lipolysis within adipocytes, we measured by RT-
qPCR the level of HSL transcripts in adipocytes obtained from
ZAG deﬁcient and wild-type littermates. We could not observe
any notable diﬀerences in the HSL levels nor could we do so
for transcripts of other key molecules of lipid metabolism i.e.
lipoprotein lipase (LPL) or fatty acid synthase (FAS) in the
same setting (data not shown).
A bodywide screen helped establish the pattern of ZAG
expression both at mRNA and protein levels, hence sorting
out through the often limited and equally conﬂicting previ-
ously published results [25,27,35]. Our data clearly demon-
strate that ZAG protein is ubiquitously and constitutively
expressed in mouse, with an especially high level in the liver
compared to other organs tested. The reason why there is rel-
atively little ZAG mRNA present in most tissues, versus quitedetectable quantities of protein might be one or several of the
following generic situations: either ZAG mRNA is highly sta-
ble and/or the protein has a long half life, and/or ZAG is cap-
tured and internalized by low producing cells/tissues.
In conclusion, the work described here establishes a few facts
about the enigmatic ZAG molecule. First, ZAG’s expression
pattern is much wider than previously thought and not limited
to the adipose tissue or various epithelia. Second, in vivo abla-
tion of ZAG in mouse is at the origin of signiﬁcant weight gain
which appears to correlate with a reduction of lipolysis in adi-
pocytes. Finally, and although the immune system does not
seem to be signiﬁcantly altered in the absence of ZAG, subtle
dysfunctions in minute, yet important, subsets of T cells could
not be presently excluded. In ﬁne, ZAG KO mice described
here should prove to be a valuable tool to further characterize
the role of ZAG in physiology, oncology, immunology and last
but not least obesity and cachexia where a therapeutic use of
the molecule may seem rational.
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